Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.
In any event, it will take a few years until Shield can both obtain FDA approval and reimbursement.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”